[go: up one dir, main page]

ECSP19026680A - COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING - Google Patents

COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING

Info

Publication number
ECSP19026680A
ECSP19026680A ECSENADI201926680A ECDI201926680A ECSP19026680A EC SP19026680 A ECSP19026680 A EC SP19026680A EC SENADI201926680 A ECSENADI201926680 A EC SENADI201926680A EC DI201926680 A ECDI201926680 A EC DI201926680A EC SP19026680 A ECSP19026680 A EC SP19026680A
Authority
EC
Ecuador
Prior art keywords
compounds
general formula
benzo
thiophene compounds
sting agonists
Prior art date
Application number
ECSENADI201926680A
Other languages
English (en)
Inventor
P Jewell James
M Haidle Andrew
Chang Wonsuk
D Altman Michael
Lim Jongwon
A Larsen Matthew
D Cash Brandon
N Cumming Jared
J Henderson Timothy
Tyagarajan Sriram
Wesley Trotter Benjamin
Lu Min
Siu Tony
D Otte Ryan
Liang Rui
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP19026680A publication Critical patent/ECSP19026680A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan los compuestos de fórmula general (Ia), los compuestos de fórmula general (Ia´), los compuestos de fórmula general (Ib), los compuestos de fórmula general (Ib´), los compuestos de fórmula general (I), los compuestos de fórmula general (I´), y sus sales farmacéuticamente aceptables, en las que R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, y X3 se definen en el presente documento, que pueden ser útiles como inductores de la producción de interferones de tipo I, específicamente como agentes activos de STING. También se proporcionan procedimientos para la síntesis y uso de compuestos de la divulgación.
ECSENADI201926680A 2016-10-04 2019-04-12 COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING ECSP19026680A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662404062P 2016-10-04 2016-10-04

Publications (1)

Publication Number Publication Date
ECSP19026680A true ECSP19026680A (es) 2019-04-30

Family

ID=60084122

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201926680A ECSP19026680A (es) 2016-10-04 2019-04-12 COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING

Country Status (39)

Country Link
US (3) US10414747B2 (es)
EP (1) EP3523287B1 (es)
JP (1) JP6636673B2 (es)
KR (1) KR102312721B1 (es)
CN (1) CN110036001B (es)
AR (1) AR109788A1 (es)
AU (1) AU2017339418C1 (es)
CA (1) CA3038903C (es)
CL (1) CL2019000902A1 (es)
CO (1) CO2019003349A2 (es)
CR (1) CR20190168A (es)
CY (1) CY1124837T1 (es)
DK (1) DK3523287T3 (es)
DO (1) DOP2019000083A (es)
EA (1) EA037626B1 (es)
EC (1) ECSP19026680A (es)
ES (1) ES2893532T3 (es)
GE (2) GEP20217285B (es)
HR (1) HRP20211617T1 (es)
HU (1) HUE056502T2 (es)
IL (1) IL265678B2 (es)
JO (1) JOP20190070B1 (es)
LT (1) LT3523287T (es)
MA (1) MA46452B1 (es)
MD (1) MD3523287T2 (es)
MX (1) MX386187B (es)
MY (1) MY196383A (es)
NI (1) NI201900029A (es)
PE (1) PE20190705A1 (es)
PH (1) PH12019500712B1 (es)
PL (1) PL3523287T3 (es)
PT (1) PT3523287T (es)
RS (1) RS62410B1 (es)
SG (1) SG10202008647TA (es)
SI (1) SI3523287T1 (es)
TN (2) TN2020000158A1 (es)
TW (1) TWI796306B (es)
UA (1) UA125223C2 (es)
WO (1) WO2018067423A1 (es)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3692996A1 (en) 2016-03-18 2020-08-12 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
CA3029644A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
MA46452B1 (fr) * 2016-10-04 2021-10-29 Merck Sharp & Dohme Composés de benzo[b]thiophéne en tant qu'agonistes de sting
CN117402852A (zh) 2016-10-14 2024-01-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
EP3609922A2 (en) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
CA3071538A1 (en) * 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment
AU2018311965A1 (en) * 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
JP7262451B2 (ja) * 2017-10-05 2023-04-21 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｓｔｉｎｇアゴニストの投与方法
SG11202004113VA (en) 2017-11-10 2020-06-29 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
KR20240161203A (ko) 2017-12-01 2024-11-12 더 텍사스 에이 & 엠 유니버시티 시스템 엔젤만 증후군 안티센스 치료
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
WO2019195063A1 (en) * 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
KR102755259B1 (ko) * 2018-04-03 2025-01-15 머크 샤프 앤드 돔 엘엘씨 Sting 효능제로서의 벤조티오펜 및 관련 화합물
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
GB201807924D0 (en) * 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
MA52754A (fr) 2018-05-25 2021-04-14 Incyte Corp Composés hétérocycliques tricycliques en tant qu'activateurs de sting
JP7440504B2 (ja) 2018-07-10 2024-02-28 エフ－スター・セラピューティクス・インコーポレイテッド 疾患を治療するための化合物、組成物及び方法
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
US20210238287A1 (en) * 2018-07-26 2021-08-05 Bristol-Myers Squibb Company LAG-3 Combination Therapy for the Treatment of Cancer
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
IL315138A (en) 2018-09-06 2024-10-01 Daiichi Sankyo Co Ltd Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
TW202446772A (zh) 2018-10-11 2024-12-01 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
SG11202103839UA (en) 2018-10-31 2021-05-28 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
CN111393405B (zh) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
CN111393404B (zh) * 2019-01-02 2023-02-17 中国科学院上海药物研究所 一类苯并噻吩类化合物及其药物组合物及应用
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
CA3129022C (en) 2019-03-07 2023-08-01 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020221038A1 (zh) 2019-04-30 2020-11-05 四川科伦博泰生物医药股份有限公司 苯并噻吩类化合物及其制备方法和用途
CN111848572B (zh) * 2019-04-30 2023-03-31 四川科伦博泰生物医药股份有限公司 酰胺类化合物及其制备方法和用途
CN111848573B (zh) * 2019-04-30 2023-04-07 四川科伦博泰生物医药股份有限公司 苯并噻吩酰胺类化合物及其制备方法和用途
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
JP2022543086A (ja) 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
JP7414965B2 (ja) * 2019-08-21 2024-01-16 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの二環式アゴニスト
JP7485399B2 (ja) * 2019-08-21 2024-05-16 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの単環式アゴニスト
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
PH12022551030A1 (en) * 2019-10-28 2023-04-24 Shanghai Inst Materia Medica Cas Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US20230074558A1 (en) * 2019-12-06 2023-03-09 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
JP7662644B2 (ja) 2019-12-18 2025-04-15 シーティーエックスティー・ピーティーワイ・リミテッド 化合物
CN115209921B (zh) 2020-03-06 2025-06-24 第一三共株式会社 包含环状二核苷酸衍生物的抗体药物偶联物
KR20220156884A (ko) 2020-03-20 2022-11-28 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
JP2023520513A (ja) 2020-04-02 2023-05-17 メルサナ セラピューティクス インコーポレイテッド Ｓｔｉｎｇアゴニストを含む抗体薬物コンジュゲート
EP4134134A4 (en) 2020-04-10 2023-12-27 ONO Pharmaceutical Co., Ltd. STING AGONISTIC COMPOUND
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
AU2021270750B2 (en) 2020-05-13 2024-06-13 Massachusetts Institute Of Technology Compositions of polymeric microdevices and their use in cancer immunotherapy
CN113861161A (zh) * 2020-06-30 2021-12-31 上海海和药物研究开发股份有限公司 一种芳基并芳杂环衍生物及其制备方法和用途
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CA3191395A1 (en) 2020-09-02 2022-03-10 Daiichi Sankyo Company, Limited Novel endo-.beta.-n-acetylglucosaminidase
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
CN113429384B (zh) * 2021-05-12 2022-04-08 中山大学附属第五医院 一类干扰素基因刺激因子靶向的放射性pet显像剂
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
JP7654118B2 (ja) 2021-06-23 2025-03-31 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117836007A (zh) * 2021-07-13 2024-04-05 南京大学 一种pt偶联物及其用途
CN113429387B (zh) * 2021-07-27 2022-10-28 中国药科大学 一种苯并[b]硒吩类STING调控剂、其制备方法及用途
CN115772154B (zh) * 2021-09-08 2024-04-30 上海交通大学 一类含有氘取代的苯并噻吩类衍生物及其制备与用途
EP4488378A1 (en) 2022-03-02 2025-01-08 Daiichi Sankyo Company, Limited Method for producing fc-containing molecule
WO2023211940A1 (en) * 2022-04-25 2023-11-02 The Regents Of The University Of Michigan Sting agonists, formulations, and uses thereof
WO2023211930A1 (en) * 2022-04-25 2023-11-02 The Regents Of The University Of Michigan Dual functioning immune modulating compounds, formulations, and uses thereof
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
EP4671250A1 (en) * 2023-02-24 2025-12-31 Shenzhen Genuine Biotechnology Co., Ltd. Tricyclic Sting Agonist and its Use
CN116354922B (zh) * 2023-03-31 2025-04-25 药康众拓(江苏)医药科技有限公司 氘代苯并噻吩类化合物及其药物组合物和用途
WO2024211577A1 (en) 2023-04-05 2024-10-10 Massachusetts Institute Of Technology Hybrid polymeric systems and methods of use thereof
WO2025007743A1 (en) * 2023-07-04 2025-01-09 Primelink Biotherapeutics (Shenzhen) Co., Ltd. Sting agonists and uses thereof
WO2025096619A1 (en) * 2023-10-30 2025-05-08 The Regents Of The University Of Michigan Dual functioning immune modulating compounds, formulations, and uses thereof
WO2025096584A1 (en) * 2023-10-30 2025-05-08 The Regents Of The University Of Michigan Sting agonists, compositions, and uses thereof
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof
CN121293183A (zh) * 2025-12-15 2026-01-09 北京悦康科创医药科技股份有限公司 含有苯并噻吩结构用于激活sting通路的佐剂脂质及其组合物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB532822A (en) * 1939-08-11 1941-01-31 John David Kendall Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters
GB1383114A (en) * 1972-06-22 1975-02-05 English Electric Valve Co Ltd Magnetrons
US4342690A (en) 1980-04-28 1982-08-03 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
US4342689A (en) 1980-04-28 1982-08-03 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
US4299769A (en) * 1980-04-28 1981-11-10 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
US4342691A (en) 1980-04-28 1982-08-03 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
EP0146243A1 (en) 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
ATE128135T1 (de) * 1988-07-11 1995-10-15 Akzo Nobel Nv Pyridazinon-derivate.
EP0664792B1 (en) 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
US5569655A (en) 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
AU757409B2 (en) 1998-06-03 2003-02-20 Merck & Co., Inc. Hiv integrase inhibitors
US6262055B1 (en) 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
EP1280764B1 (en) 2000-03-24 2010-11-24 Methylgene, Inc. Inhibitors of histone deacetylase
AU2002234755A1 (en) 2001-02-26 2002-09-12 Pharma Pacific Pty Ltd Interferon-alpha induced gene
EP2243493A1 (en) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
AU2004268012B2 (en) 2003-09-02 2008-11-20 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1729781B1 (en) 2004-03-15 2012-10-24 Karaolis, David K. R. A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
KR101562580B1 (ko) 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2010027827A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
CN102264762B (zh) 2008-09-26 2018-03-27 达纳-法伯癌症研究公司 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
WO2010047774A2 (en) 2008-10-20 2010-04-29 The Texas A & M University System Inhibitors of mycobacterium tuberculosis malate synthase, methods of marking and uses thereof
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2012068702A1 (zh) * 2010-11-23 2012-05-31 中国医学科学院医药生物技术研究所 苯并五元不饱和杂环类化合物及其制备方法
JP5887947B2 (ja) 2011-03-28 2016-03-16 ソニー株式会社 透明導電膜、ヒータ、タッチパネル、太陽電池、有機ｅｌ装置、液晶装置および電子ペーパ
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
SG10201606284UA (en) 2011-08-01 2016-09-29 Genentech Inc Methods Of Treating Cancer Using Pd-1 Axis Binding Antagonists And Mek Inhibitors
SG10201610251PA (en) 2012-06-08 2017-01-27 Aduro Biotech Compositions and methods for cancer immunotherapy
CN103840995B (zh) 2012-11-26 2017-10-24 华为技术有限公司 Ip报文处理方法、装置及网络系统
PT2931738T (pt) 2012-12-13 2019-04-10 Aduro Biotech Inc Composições compreendendo nucleótidos cíclicos de purina com estereoquímica definida e métodos para a sua preparação e utilização
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014099824A1 (en) 2012-12-19 2014-06-26 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US20140329889A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
JP6400082B2 (ja) 2013-05-18 2018-10-03 アデュロ バイオテック，インコーポレイテッド 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
PT2996473T (pt) 2013-05-18 2019-11-18 Univ California Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão''
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
CA2931146C (en) 2013-11-22 2022-06-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN103908468B (zh) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
WO2015189117A1 (de) 2014-06-12 2015-12-17 Bayer Pharma Aktiengesellschaft Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
CN107106589A (zh) 2014-12-17 2017-08-29 立博美华基因科技有限责任公司 用cGAMP或cGAsMP治疗癌症的方法
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
TW201717968A (zh) 2015-07-14 2017-06-01 春季銀行製藥公司 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
EP3325473A4 (en) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Compounds and uses thereof in the treatment of cancer and other medical disorders
SG10202010609QA (en) 2015-08-13 2020-11-27 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists
US9809597B2 (en) 2015-08-20 2017-11-07 The Board Of Trustees Of The Leland Stanford Junior University Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
EP3368072A4 (en) 2015-10-28 2019-07-03 Aduro BioTech, Inc. COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
CN109451740B (zh) 2016-01-11 2022-09-02 先天肿瘤免疫公司 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
EP3692996A1 (en) 2016-03-18 2020-08-12 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
IL295649B2 (en) 2016-04-07 2025-12-01 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
ES2993451T3 (en) 2016-06-13 2024-12-30 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
MA46452B1 (fr) * 2016-10-04 2021-10-29 Merck Sharp & Dohme Composés de benzo[b]thiophéne en tant qu'agonistes de sting
AU2018311965A1 (en) * 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
CA3071538A1 (en) * 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment

Also Published As

Publication number Publication date
HRP20211617T1 (hr) 2022-03-04
MX386187B (es) 2025-03-18
PL3523287T3 (pl) 2021-12-20
HUE056502T2 (hu) 2022-02-28
US20190337918A1 (en) 2019-11-07
EP3523287B1 (en) 2021-09-01
PH12019500712A1 (en) 2019-12-02
JP2019534876A (ja) 2019-12-05
KR20190056432A (ko) 2019-05-24
US20190337917A1 (en) 2019-11-07
TW201817723A (zh) 2018-05-16
GEAP202115066A (en) 2021-04-12
TWI796306B (zh) 2023-03-21
KR102312721B1 (ko) 2021-10-13
US20180093964A1 (en) 2018-04-05
SG10202008647TA (en) 2020-10-29
RS62410B1 (sr) 2021-10-29
EA201990846A1 (ru) 2019-08-30
DOP2019000083A (es) 2019-07-15
ES2893532T3 (es) 2022-02-09
AU2017339418A1 (en) 2019-04-18
MA46452A (fr) 2021-04-07
MY196383A (en) 2023-03-28
JOP20190070A1 (ar) 2019-04-04
CN110036001B (zh) 2022-03-22
NI201900029A (es) 2019-05-13
CN110036001A (zh) 2019-07-19
CO2019003349A2 (es) 2019-04-12
BR112019006816A2 (pt) 2019-07-30
EA037626B1 (ru) 2021-04-22
AU2017339418C1 (en) 2020-12-17
EP3523287A1 (en) 2019-08-14
US10730849B2 (en) 2020-08-04
TN2020000158A1 (en) 2022-04-04
MA46452B1 (fr) 2021-10-29
UA125223C2 (uk) 2022-02-02
GEP20217285B (en) 2021-08-10
DK3523287T3 (da) 2021-10-18
LT3523287T (lt) 2021-11-10
SI3523287T1 (sl) 2021-11-30
MX2019003829A (es) 2019-07-01
AU2017339418B2 (en) 2020-04-16
PH12019500712B1 (en) 2023-05-10
CA3038903A1 (en) 2018-04-12
PE20190705A1 (es) 2019-05-17
AR109788A1 (es) 2019-01-23
WO2018067423A1 (en) 2018-04-12
IL265678A (en) 2019-05-30
CL2019000902A1 (es) 2019-06-21
MD3523287T2 (ro) 2021-12-31
JP6636673B2 (ja) 2020-01-29
US10703738B2 (en) 2020-07-07
IL265678B2 (en) 2023-06-01
US10414747B2 (en) 2019-09-17
CY1124837T1 (el) 2022-11-25
CR20190168A (es) 2019-05-17
BR112019006816A8 (pt) 2023-02-07
PT3523287T (pt) 2021-10-06
CA3038903C (en) 2021-07-27
JOP20190070B1 (ar) 2023-09-17
TN2020000159A1 (en) 2022-04-04

Similar Documents

Publication Publication Date Title
ECSP19026680A (es) COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
ECSP19028657A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
UY35275A (es) Derivados de aminopirazina
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
CR20170496A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY39705A (es) Novedosos compuestos útiles como agonistas de sting y sus usos
GT201100039A (es) Agentes antifúngicos
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.
AR100620A1 (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
ECSP11010817A (es) Agentes antifúngicos